Anifrolumab (Systemic)

Brand names: Saphnelo
Drug class: Antineoplastic Agents

Usage of Anifrolumab (Systemic)

Systemic Lupus Erythematosus

Treatment of moderate to severe systemic lupus erythematosus (SLE) in adults; use in conjunction with other standard SLE therapies (e.g., corticosteroids, antimalarials, immunosuppressant agents).

Not evaluated and therefore not recommended in patients with severe active lupus nephritis or severe active CNS lupus.

The European Alliance of Associations for Rheumatology (EULAR) has provided guidelines on the management of SLE. In the 2019 EULAR guidelines, biologic agents are recommended in patients with an inadequate response to standard therapies; however, anifrolumab was not yet available when these guidelines were published.

Relate drugs

How to use Anifrolumab (Systemic)

General

Pretreatment Screening

  • Consider the potential risks and benefits before initiating anifrolumab in patients with a chronic infection, a history of recurrent infections, or known risk factors for infection.
  • Consider the potential risks and benefits before initiating anifrolumab in patients with known risks factors for the development or recurrence of malignancy.
  • Update immunizations according to current immunization guidelines prior to initiating treatment with anifrolumab.
  • Patient Monitoring

  • Monitor for signs and symptoms of hypersensitivity and infusion-related reactions.
  • Monitor for signs and symptoms of infection during treatment.
  • Premedication and Prophylaxis

  • Consider premedication before infusions in patients with a history of hypersensitivity or infusion-related reactions.
  • Dispensing and Administration Precautions

  • Administer by healthcare providers prepared to manage hypersensitivity reactions and infusion-related reactions.
  • Administration

    IV Administration

    Administer by IV infusion over 30 minutes every 4 weeks.

    Commercially available as an injection concentrate that must be diluted prior to IV administration.

    Anifrolumab injection is preservative-free. Discard any unused portion left in the single-use vial after preparation.

    If a planned infusion is missed, administer the missed infusion as soon as possible. Maintain a minimum interval of 14 days between infusions.

    Do not administer other medications concomitantly via the same infusion line.

    Interrupt the infusion if the patient develops any signs of adverse reactions, including infusion or hypersensitivity reactions.

    Dilution

    To prepare the diluted infusion solution, withdraw and discard 2 mL of solution from a 50 mL or 100 mL 0.9% sodium chloride injection bag using aseptic technique. Then, withdraw 2 mL (300 mg) of anifrolumab concentrate for injection from the single-use vial, and transfer to the 0.9% sodium chloride injection bag. Gently invert the bag of anifrolumab to mix; do not shake. Use the diluted solution immediately after preparation or store at room temperature for up to 4 hours or under refrigeration for up to 24 hours. If refrigerated, allow the diluted solution to come to room temperature prior to administration.

    Rate of Administration

    Administer the diluted solution via IV infusion over 30 minutes through an IV line containing a sterile, low-protein binding, in-line or add-on, 0.2–15-micron filter.

    Dosage

    Adults

    Systemic Lupus Erythematosus IV

    300 mg by IV infusion every 4 weeks.

    Special Populations

    Hepatic Impairment

    No specific dosage recommendations at this time.

    Renal Impairment

    No specific dosage recommendations at this time.

    Geriatric Use

    No specific dosage recommendations at this time.

    Warnings

    Contraindications

    History of anaphylaxis to anifrolumab.

    Warnings/Precautions

    Serious Infections

    Serious, sometimes fatal, infections reported. Increased risk of respiratory infections and herpes zoster (including disseminated herpes zoster).

    Consider risks and benefits of anifrolumab in patients with chronic infections, a history of recurrent infections, or known risk factors for infection. Avoid starting anifrolumab during an active infection until infection is treated or resolved. If an infection develops while on anifrolumab therapy or patient is not responsive to standard anti-infective treatment, seek medical treatment for the infection and monitor closely; consider interruption of therapy and closely monitor patient until resolution of the infection.

    Hypersensitivity Reactions

    Serious hypersensitivity reactions reported following anifrolumab administration; angioedema has also occurred.

    Other hypersensitivity and infusion-related reactions have been reported. Consider premedication in patients with a history of these reactions prior to infusion of anifrolumab.

    Administer anifrolumab only under the supervision of a healthcare provider prepared to manage hypersensitivity reactions, including anaphylaxis, and infusion-related reactions. If there is a serious infusion-related or hypersensitivity reaction (e.g., anaphylaxis), immediately stop administration and initiate appropriate therapy.

    Malignancy

    Immunosuppressants are associated with an increased risk of malignancies; specific risk for malignancy development in patients treated with anifrolumab not known.

    Prior to initiating anifrolumab, consider benefits and risks in patients with known risk factors for the development or recurrence of malignancy. If malignancy develops during treatment, consider risk versus benefit of continuing anifrolumab.

    Immunization

    Update immunizations prior to initiation of anifrolumab in accordance with current immunization guidelines. Avoid use of live or live-attenuated vaccines during treatment.

    Not Recommended for Concomitant Use with other Biologic Therapies

    Not studied and not recommended for use in combination with other biologic agents, including B-cell targeted therapies.

    Immunogenicity

    Potential for immunogenicity. Anti-anifrolumab antibodies detected. Clinical relevance not known.

    Specific Populations

    Pregnancy

    Limited human data available to inform drug-associated risk. For more information, contact the pregnancy exposure registry that monitors pregnancy outcomes in women exposed to anifrolumab at 1-877-693-9268.

    Lactation

    Not known whether anifrolumab is distributed into human milk; however, the drug has been detected in animal milk. Consider the benefits of breast-feeding, the potential for adverse effects from anifrolumab exposure to the breast-fed infant, and the mother’s clinical need for anifrolumab.

    Pediatric Use

    Safety and efficacy not established.

    Geriatric Use

    Insufficient experience in patients ≥65 years of age to determine whether they respond differently from younger adult patients.

    Hepatic Impairment

    Based on pharmacokinetic analyses, baseline hepatic biomarkers (ALT and AST levels ≤2 times the ULN and total bilirubin) had no clinically relevant effects on anifrolumab clearance.

    Renal Impairment

    Based on pharmacokinetic analyses, clearance of anifrolumab similar between normal (eGFR >90 mL/minute/1.73 m2) and mild to moderate renal impairment (eGFR 30–89 mL/minute/1.73 m2).

    Not evaluated in severe renal impairment or ESRD (eGFR <30 mL/minute/1.73 m2), but anifrolumab is not renally cleared.

    Common Adverse Effects

    Adverse drug reactions (incidence ≥5%): nasopharyngitis, upper respiratory tract infections, bronchitis, infusion-related reactions, herpes zoster, cough.

    What other drugs will affect Anifrolumab (Systemic)

    No formal drug interaction studies have been conducted.

    Specific Drugs

    Drug

    Interaction

    ACE Inhibitors

    Concentrations not meaningfully altered

    Antimalarials

    Concentrations not meaningfully altered

    Corticosteroids

    Concentrations not meaningfully altered

    Immunosuppressants (e.g., azathioprine, methotrexate, mycophenolate mofetil, mycophenolic acid, mizoribine)

    Concentrations not meaningfully altered

    NSAIAs

    Concentrations not meaningfully altered

    Statins

    Concentrations not meaningfully altered

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords

    AI Assitant